| Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. | |
| | |
MedLine Citation:
|
PMID: 20623622 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rett syndrome is a pediatric neurological condition that affects primarily girls. Approximately 30% of Rett syndrome cases arise from point mutations that introduce a premature stop codon into the MECP2 gene. Several studies have now shown that certain aminoglycosides can facilitate read-through of some types of nonsense mutations in a context-dependent manner and allow the generation of a full-length protein. It remains mostly unclear whether different nonsense mutations of MECP2 will be responsive to aminoglycoside treatment. In this study, we tested whether the common premature terminating mutations of MECP2 seen in Rett syndrome cases can be partially suppressed by aminoglycoside administration. Our results show that aminoglycosides allow different mutant forms of MECP2 to be overcome in transiently transfected HEK293 cells, but with differing levels of efficiency. In addition, we also show that aminoglycosides increased the prevalence of full-length MeCP2 protein in a dose-dependent manner in a lymphocyte cell line derived from a Rett syndrome girl with the R255X mutation. This study helps to establish the "proof of principle" that some nonsense mutations causing Rett syndrome can be at least partially suppressed by drug treatment. |
| | |
Authors:
|
Andreea C Popescu; Elena Sidorova; Guangming Zhang; James H Eubanks |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of neuroscience research Volume: 88 ISSN: 1097-4547 ISO Abbreviation: J. Neurosci. Res. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-13 Completed Date: 2010-10-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600111 Medline TA: J Neurosci Res Country: United States |
Other Details:
|
Languages: eng Pagination: 2316-24 Citation Subset: IM |
Copyright Information:
|
(c) 2010 Wiley-Liss, Inc. |
Affiliation:
|
Division of Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amikacin
/
pharmacology Aminoglycosides / pharmacology* Blotting, Western Cell Line Cell Nucleus / chemistry, drug effects Child Codon, Nonsense / drug effects* Dose-Response Relationship, Drug Female Gentamicins / pharmacology Humans Methyl-CpG-Binding Protein 2 / biosynthesis*, genetics Protein Synthesis Inhibitors / pharmacology* RNA, Messenger / biosynthesis, genetics Rett Syndrome / genetics* Reverse Transcriptase Polymerase Chain Reaction Transfection |
| Grant Support | |
ID/Acronym/Agency:
|
MOP-57765//Canadian Institutes of Health Research; MOP-81104//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Aminoglycosides; 0/Codon, Nonsense; 0/Gentamicins; 0/MECP2 protein, human; 0/Methyl-CpG-Binding Protein 2; 0/Protein Synthesis Inhibitors; 0/RNA, Messenger; 37517-28-5/Amikacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple scleros...
Next Document: Antioxidant activity of yellow dock (Rumex crispus L., Polygonaceae) fruit extract.